Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Background: Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor developed as a potential treatment for Alzheimer’s disease (AD). Objective: To evaluate the safety, tolerability, and efficacy of sembragiline in patients with moderate AD. Methods: In this Phase II study (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Nave, Stephane, Doody, Rachelle S., Boada, Mercè, Grimmer, Timo, Savola, Juha-Matti, Delmar, Paul, Pauly-Evers, Meike, Nikolcheva, Tania, Czech, Christian, Borroni, Edilio, Ricci, Benedicte, Dukart, Juergen, Mannino, Marie, Carey, Tracie, Moran, Emma, Gilaberte, Inma, Muelhardt, Nicoletta Milani, Gerlach, Irene, Santarelli, Luca, Ostrowitzki, Susanne, Fontoura, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523913/
https://www.ncbi.nlm.nih.gov/pubmed/28550255
http://dx.doi.org/10.3233/JAD-161309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523913/
https://www.ncbi.nlm.nih.gov/pubmed/28550255
http://dx.doi.org/10.3233/JAD-161309

Ejemplares similares